
James Kearns, MD, discusses genetic correction of prostate-specific antigen (PSA) and how it can reduce the number of patients diagnosed with potentially insignificant prostate cancer

Your AI-Trained Oncology Knowledge Connection!


Published: September 3rd 2015 | Updated: